Abstract
It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
Keywords: Atherogenesis, biomarker, cardiovascular disease, C-reactive protein, high sensitivity C-reactive protein, inflammation, prevention.
Current Pharmaceutical Analysis
Title:High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Volume: 11 Issue: 1
Author(s): Andreja Trpkovic, Julijana Stanimirovic, Ivana Resanovic, Petar Otasevic, Danimir Jevremovic, Radak Djordje and Esma R. Isenovic
Affiliation:
Keywords: Atherogenesis, biomarker, cardiovascular disease, C-reactive protein, high sensitivity C-reactive protein, inflammation, prevention.
Abstract: It is now recognized that inflammatory processes regulate all stages of atherosclerosis, from disease initiation to thrombotic complications. C-reactive protein (CRP) is a plasmatic protein used as a general marker of inflammation. The high sensitivity C-reactive protein (hsCRP) refers to the measurement of CRP in blood samples using assays with sufficient sensitivity to quantify low (baseline) levels of this biomarker. Low-grade chronic inflammatory processes are linked to atherosclerosis and may be screened with the use of hsCRP, thus providing additional information in cardiovascular risk prediction. This review elaborates the role of CRP in atherogenesis and the value of hsCRP as a biomarker in cardiovascular risk prediction in both primary and secondary prevention setting.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stanimirovic Julijana, Resanovic Ivana, Otasevic Petar, Jevremovic Danimir, Djordje Radak and Isenovic R. Esma, High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction, Current Pharmaceutical Analysis 2015; 11 (1) . https://dx.doi.org/10.2174/1573412910666140822003911
DOI https://dx.doi.org/10.2174/1573412910666140822003911 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology Psychological Stress and the Development of Heart Disease
Current Psychiatry Reviews Achieving Better Blood Pressure Control in High-Risk Patients with Type 2 Diabetes Using Combination Antihypertensive Therapy
Vascular Disease Prevention (Discontinued) Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Safety and Efficacy of Novel Oral Anticoagulants: A Comparison to Vitamin K Antagonists
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology The Management of the Infected Diabetic Foot
Current Diabetes Reviews Editorial [Hot Topic: Novel Pharmacological Therapies for Cardiac Hypertrophy and Heart Failure (Executive Guest Editor: Peter M. Kang)]
Current Pharmaceutical Design Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia
Current Alzheimer Research Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Fluoroquinolones: Blessings Or Curses
Current Drug Targets